Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.48 |
| ▸ | MEN1 | O00255 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694342 | 0.83 | POLB (0.58) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL693129 | 0.83 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL694086 | 0.83 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL694484 | 0.82 | ALDH1A1 (0.48) | KMT2AMEN1ALDH1A1MAPTPKM | |
| SCHEMBL3108469 | 0.79 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL694249 | 0.78 | KMT2A (0.60) | KMT2AMEN1ALDH1A1MAPTPKM | |
| SCHEMBL693480 | 0.78 | OPRM1 (0.49) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL692945 | 0.78 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL694495 | 0.78 | OPRM1 (0.51) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL694345 | 0.77 | GAA (0.47) | KMT2AMEN1ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502921-B1 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2502921-B1 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2502921-A1 | Arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502921-A1 | Arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2421838-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010123960-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123960-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | KMT2A 2688/4885MEN1 4563/4885ALDH1A1 2454/4885 |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | KMT2A 2688/4885MEN1 4563/4885ALDH1A1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.